The DOI matches its Crossref record.
A Comparison of Danaparoid and Lepirudin in Heparin-induced Thrombocytopenia
Abstract
Summary: Heparin-induced thrombocytopenia (HIT) is a hypercoagulable syndrome strongly associated with thrombosis that is usually treated with drugs that inhibit factor Xa (danaparoid) or thrombin (lepirudin). In the present study the outcome of HIT-patients treated with danaparoid or lepirudin was compared using the single or combined endpoints of new thromboembolic complications (new TECs), amputations and/or death, and major bleeding. HIT-patients treated with lepirudin were enrolled in two prospective trials and patients, who were identified in the same two laboratories during the same time period, who were not enrolled into these studies but treated with danaparoid, were assessed retrospectively according to a standardized questionnaire. 126 danaparoid (60.3% female) and 175 lepirudin treated patients (58.3% female) fulfilled the same inclusion and exclusion criteria. In a time-to-eventanalysis the cumulative risk of combined endpoint was higher in HIT-patients without thromboembolic complication at baseline treated with danaparoid (usually in prophylactic dose 750 anti-factor Xa units b.i.d. or t.i.d. s.c.) as compared to lepirudin (aPTT adjusted) (P = 0.020). Whereas HIT-patients with TEC at baseline who were usually treated with therapeutic dose had a similar outcome in both treatment groups (P = 0.913). Major bleeding occurred in 2.5% (95% CI 0.5-7.0%) of danaparoid treated patients as compared to 10.4% (95% CI 6.3-15.9%) of lepirudin treated patients until day 42 (P = 0.009). This indicates that the efficacies of therapeutic doses of danaparoid or lepirudin in preventing death, amputation or new TEC in HIT-patients do not differ largely, but the risk of bleeding seems to be higher in lepirudin treated patients. The prophylactic dose of danaparoid approved in the European Union for HIT without TEC at baseline seems suboptimal. A prospective comparative trial is required to verify these preliminary conclusions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Treatment and Prevention of Heparin-Induced Thrombocytopenia
Linkins, L.-A., Dans, A. L., Moores, L. K., Bona, R., Davidson, B. L., Schulman, S., & Crowther, M. (2012) · Chest · doi:10.1378/chest.11-2303 · Cited by 1,018
Treatment and Prevention of Heparin-Induced Thrombocytopenia
Warkentin, T. E., Greinacher, A., Koster, A., & Lincoff, A. M. (2008) · Chest · doi:10.1378/chest.08-0677 · Cited by 816
Self-citationHeparin-Induced Thrombocytopenia: Recognition, Treatment, and Prevention
Warkentin, T. E., & Greinacher, A. (2004) · Chest · doi:10.1378/chest.126.3_suppl.311s · Cited by 809
Self-citationCuker, A., Arepally, G. M., Chong, B. H., Cines, D. B., Greinacher, A., Gruel, Y., Linkins, L. A., Rodner, S. B., Selleng, S., Warkentin, T. E., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018024489 · Cited by 750
Self-citationHemorrhagic Complications of Anticoagulant and Thrombolytic Treatment
Schulman, S., Beyth, R. J., Kearon, C., & Levine, M. N. (2008) · Chest · doi:10.1378/chest.08-0674 · Cited by 740
Metadata
- Authors
- Farner, B., Eichler, P., Kroll, H., & Greinacher, A.
- Venue
- Thrombosis and Haemostasis
- Publisher
- Georg Thieme Verlag KG
- Published
- 2001
- Volume
- 85
- Issue
- 06
- Pages
- 950-957
- ISSN
- 0340-6245 (ISSN-L)
- 2567-689X
- OpenAlex
- W1889263859
- Cited by
- 192
- References
- 0
- FWCI
- 14.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Comparison of Danaparoid and Lepirudin in Heparin-induced Thrombocytopenia. https://app.cochat.ai/papers/10.1055/s-0037-1615946
- The paper
- Farner, B., Eichler, P., Kroll, H., & Greinacher, A. (2001). A Comparison of Danaparoid and Lepirudin in Heparin-induced Thrombocytopenia. Thrombosis and Haemostasis. https://doi.org/10.1055/s-0037-1615946
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.